Cited by 524Diabetes Treatment and ManagementLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes

Open access

Tiikkainen, Mirja, Häkkinen, Anna-Maija, Korsheninnikova, Elena, Nyman, Tuulikki, Mäkimattila, Sari, Yki-Järvinen, Hannele·2004·Diabetes

DOI 10.2337/diabetes.53.8.2169

Open this paper in CoChat — free account Open PDF

Abstract

Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 +/- 3 years, fasting plasma glucose 152 +/- 9 mg/dl, BMI 30.6 +/- 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 +/- 4 vs. 82 +/- 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 +/- 3 vs. 7 +/- 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 +/- 3 to 14 +/- 3%, NS). Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = -0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator-activated receptor-gamma, adiponectin, and lipoprotein lipase in adipose tissue. In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. The decrease in liver fat by rosiglitazone is associated with an increase in serum adiponectin concentrations. Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diabetes.53.8.2169

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,673
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
Combs, T. P., Berg, A. H., Obici, S., Scherer, P. E., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14120 · Cited by 955
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794

Show all 48 references

Sorted by citations

Items 201–300 of 524

APOE * 3Leiden . CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome
van den Hoek, A. M., van der Hoorn, J. W. A., Maas, A. C. E., van den Hoogen, R. M., van Nieuwkoop, A., Droog, S., Offerman, E. H., Pieterman, E. J., Havekes, L. M., & Princen, H. M. G. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12252 · Cited by 50
Cardiometabolic aspects of polycystic ovarian syndrome.
Cho, L. W., Randeva, H. S., & Atkin, S. L. (2007) · PubMed Central · Cited by 50
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1518 · Cited by 50
Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
Doycheva, I., & Loomba, R. S. (2014) · Advances in Therapy · doi:10.1007/s12325-013-0084-6 · Cited by 50
PPARγ Regulation in Hypertension and Metabolic Syndrome
Stump, M., Mukohda, M., Hu, C., & Sigmund, C. D. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0601-x · Cited by 48
Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters
Wannamethee, S. G., Tchernova, J., Whincup, P. H., Lowe, G. D. O., Rumley, A., Brown, K. E., Cherry, L., & Sattar, N. A. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803544 · Cited by 48
Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
Scheen, A. J. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.11.005 · Cited by 48
A diet formula of Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma alleviates insulin resistance and hepatic steatosis in CD-1 mice and HepG2 cells
Liu, J., Zhang, H., Ji, B., Cai, S., Wang, R., Zhou, F. L., Yang, J., & Liu, H. (2014) · Food & Function · doi:10.1039/c3fo60524h · Cited by 47
Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators
Kalish, B. T., Le, H. D., Fitzgerald, J. M., Wang, S., Seamon, K. J., Gura, K. M., Gronert, K., & Puder, M. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00106.2013 · Cited by 47
Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
Pan, C. S., & Stanley, T. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00070 · Cited by 48
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease
Assy, N. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i27.4369 · Cited by 48
Methods for assessing intrahepatic fat content and steatosis
Fabbrini, E., Conte, C., & Magkos, F. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832eb587 · Cited by 45
Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice
Sundaresan, A., Radhiga, T., & Pugalendi, K. V. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.032 · Cited by 45
Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome
Matsuura, N., Asano, C., Nagasawa, K., Ito, S., Sano, Y., Minagawa, Y., Yamada, Y., Hattori, T., Watanabe, S., Murohara, T., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.099 · Cited by 45
The Adipose Tissue as an Endocrine Organ – A Nephrologists’ Perspective
Chudek, J. T., Adamczak, M., Nieszporek, T., & Więcek, A. (2006) · KARGER eBooks · doi:10.1159/000095320 · Cited by 46
The influence of thiazolidinediones on adipogenesis in vitro and in vivo: Potential modifiers of intramuscular adipose tissue deposition in meat animals1,2
Hausman, G., Poulos, S. P., Pringle, T. D., & Azain, M. J. (2008) · Journal of Animal Science · doi:10.2527/jas.2007-0219 · Cited by 44
Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes
Wilding, J. P. H., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.040 · Cited by 44
Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
Matsuba, I., Matsuba, R., Ishibashi, S., Yamashita, S., Arai, H., Yokote, K., Suganami, H., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12845 · Cited by 43
Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity
Wasada, T., Kasahara, T., Wada, J., Jimba, S., Fujimaki, R., Nakagami, T., & Iwamoto, Y. (2008) · Metabolism · doi:10.1016/j.metabol.2008.02.015 · Cited by 44
Evidence for the Importance of Adiponectin in the Cardioprotective Effects of Pioglitazone
Li, P., Shibata, R., Unno, K., Shimano, M., Furukawa, M., Ohashi, T., Cheng, X. W., Nagata, K., Ouchi, N., & Murohara, T. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.141655 · Cited by 42
Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system
Qi, L., Gröger, M., Sharma, A., Goswami, I., Chen, E., Zhong, F., Ram, A., Healy, K. E., Hsiao, E. C., Willenbring, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52258-w · Cited by 49
Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Johansson, L., Hockings, P. D., JOHNSSON, E. K., Dronamraju, N., Maaske, J., García‐Sánchez, R., & Wilding, J. P. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14004 · Cited by 43
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
Shaaban, H. H., AlZaim, I., El‐Mallah, A., Aly, R. G. M., EL‐Yazbi, A. F., & Wahid, A. M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120956 · Cited by 42
Rosiglitazone/Metformin
Wellington, K. (2005) · Drugs · doi:10.2165/00003495-200565110-00013 · Cited by 43
Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges
Xiao, J., Guo, R., Fung, M., Liong, E. C., & Tipoe, G. L. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60021-1 · Cited by 44
LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort
Bae, J. C., Han, J. M., Kwon, S. H., Jee, J. H., Yu, T. Y., Lee, M. K., & Kim, J. H. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.029 · Cited by 42
Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell, S. H., Ikura, Y., Iezzoni, J. C., & Liu, Z. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04639.x · Cited by 44
Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?
Kusaka, I., Nagasaka, S., Horie, H., & Ishibashi, S. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00857.x · Cited by 40
Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
Araki, T., Emoto, M., Teramura, M., Yokoyama, H., Mori, K., Hatsuda, S., Maeno, T., Shinohara, K., Koyama, H., Shoji, T., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.03.008 · Cited by 40
Short‐term effects of metformin in type 2 diabetes
Eriksson, A. W., Attvall, S., Bonnier, M., Eriksson, J. W., Rosander, B., & Karlsson, F. A. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00624.x · Cited by 40
Lipids in health and disease
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 41
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome: PCOS, NAFLD and metformin therapy
Preiss, D., Sattar, N., Harborne, L., Norman, J., & Fleming, R. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01825.x · Cited by 39
Suppression of Grb2 expression improved hepatic steatosis, oxidative stress, and apoptosis induced by palmitic acid in vitro partly through insulin signaling alteration
Shan, X., Miao, Y., Fan, R.-G., Song, C., Wu, G., Wan, Z., Zhu, J., Guan, S., Zha, W., Mu, X., et al. (2013) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-013-9646-9 · Cited by 39
Steatosis and Steatohepatitis: Complex Disorders
Bettermann, K., Hohensee, T., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069924 · Cited by 41
SIRT1 overexpression attenuates offspring metabolic and liver disorders as a result of maternal high‐fat feeding
Nguyen, L. T., Chen, H., Zaky, A. A., Pollock, C. A., & Saad, S. (2018) · The Journal of Physiology · doi:10.1113/jp276957 · Cited by 41
Managing diabetes and liver disease association
Hamed, A. E., Elsahhar, M., Elwan, N. M., El-Nakeep, S. A. K., Naguib, M., Soliman, H. H., Aboubakr, A. A., Sholkamy, A. A., Sedrak, H. K., Assaad, S. N., et al. (2018) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2018.08.003 · Cited by 39
Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes
Pan, H., Reifsnyder, P. C., Vance, D. E., Xiao, Q., & Leiter, E. H. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1854 · Cited by 39
A Model for Glucose, Insulin, and Beta‐Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes
Ribbing, J., Hamrén, B., Svensson, M. K. E., & Karlsson, M. O. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009349711 · Cited by 39
Short‐term effects of metformin in type 2 diabetes
Eriksson, A. W., Attvall, S., Bonnier, M., Eriksson, J. W., Rosander, B., & Karlsson, F. A. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00611.x · Cited by 39
Thiazolidinediones for Nonalcoholic Steatohepatitis — Promising but Not Ready for Prime Time
McCullough, A. J. (2006) · New England Journal of Medicine · doi:10.1056/nejme068232 · Cited by 39
Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans
Ding, L., Goossens, G. H., Oligschlaeger, Y., Houben, T., Blaak, E. E., & Shiri‐Sverdlov, R. (2019) · Diabetologia · doi:10.1007/s00125-019-05025-2 · Cited by 38
The forgotten type 2 diabetes mellitus medicine: rosiglitazone
Xu, B., Xing, A., & Li, S. (2021) · Diabetology International · doi:10.1007/s13340-021-00519-0 · Cited by 38
The role of adiposity as a determinant of an inflammatory milieu
Calabrò, P., Limongelli, G., Pacileo, G., Salvo, G. D., Golino, P., & Calabrò, R. (2008) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3282eee9a8 · Cited by 39
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus
Erdem, G., Doğru, T., Taşçı, İ., Bozoğlu, E., Muhsiroğlu, Ö., Tapan, S., Erçin, C. N., & Sönmez, A. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.07.021 · Cited by 35
Novel targets for delaying aging: The importance of the liver and advances in drug delivery
Hunt, N. J., McCourt, P., Couteur, D. G. L., & Cogger, V. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.006 · Cited by 37
Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study
Trolle, B., Lauszus, F. F., Frystyk, J., & Flyvbjerg, A. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.01.057 · Cited by 36
Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., & Sleeper, R. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.168 · Cited by 36
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease
Min, H.-K., Mirshahi, F., Verdianelli, A., Pacana, T., Patel, V., Park, C.-G., Choi, A., Lee, J.-H., Park, C.-B., Ren, S., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00390.2014 · Cited by 45
The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis
Caldwell, S. H., Patrie, J. T., Brunt, E. M., Redick, J. A., Davis, C. A., Park, S. H., & Neuschwander‐Tetri, B. A. (2007) · Hepatology · doi:10.1002/hep.21813 · Cited by 33
Insulin Resistance and Inflammation in the Early Phase of Type 2 Diabetes: Potential for Therapeutic Intervention
Schernthaner, G.-H., & Schernthaner, G. (2005) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510500236119 · Cited by 35
Pioglitazone increases non-esterified fatty acid clearance in upper body obesity
Shadid, S., & Jensen, M. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0051-0 · Cited by 35
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor γ agonist, on insulin resistance in Zucker fatty rat
Minoura, H., Takeshita, S., Yamamoto, T. S., Mabuchi, M., Hirosumi, J., Takakura, S., Kawamura, I., Seki, J., Manda, T., Ita, M., et al. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.042 · Cited by 35
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Metformin increases plasma ghrelin in Type 2 diabetes
Doogue, M. P., Begg, E. J., Moore, M. P., Lunt, H., Pemberton, C. J., & Zhang, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03372.x · Cited by 34
GQ-16, a TZD-Derived Partial PPARγ Agonist, Induces the Expression of Thermogenesis-Related Genes in Brown Fat and Visceral White Fat and Decreases Visceral Adiposity in Obese and Hyperglycemic Mice
Coêlho, M. S., de Lima, C. L., Royer, C., da Silva, J. B., Oliveira, F. C. B., Christ, C. G., Pereira, S. A., Báo, S. N., de Lima, M. D. C. A., Pitta, M. G. D. R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154310 · Cited by 36
Impact of pioglitazone on bone mineral density and bone marrow fat content
Pop, L. M., Lingvay, I., Yuan, Q., Li, X., ADAMS-HUET, B. A., & Maalouf, N. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4164-3 · Cited by 37
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
Ackerman, Z., Oron‐Herman, M., Pappo, O., Peleg, E., Safadi, R., Schmilovitz‐Weiss, H., & Grozovski, M. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00553.x · Cited by 33
The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study
Mahrooz, A., Parsanasab, H., Hashemi‐Soteh, M. B., Kashi, Z., Bahar, A., Alizadeh, A., & Mozayeni, M. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0283-8 · Cited by 33
Short-Term Continuous Subcutaneous Insulin Infusion Combined with Insulin Sensitizers Rosiglitazone, Metformin, or Antioxidant α-Lipoic Acid in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Huang, Z., Wan, X., Liu, J., Deng, W., Chen, A., Liu, L., Liu, J., Wei, G., Li, H., Fang, D., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0013 · Cited by 33
Nonalcoholic fatty liver disease and cardiovascular disease risk
Schindhelm, R. K., Diamant, M., & Heine, R. J. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0030-6 · Cited by 33
Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes
Rattarasarn, C. (2006) · Acta Physiologica · doi:10.1111/j.1748-1716.2005.01521.x · Cited by 34
Insulin Clearance: An Underappreciated Modulator of Plasma Insulin Concentration
Kim, S. H., & Reaven, G. M. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000149 · Cited by 34
Sex-dependent differences in rat hepatic lipid accumulation and insulin sensitivity in response to diet-induced obesity
Nadal-Casellas, A., Proenza, A. M., Lladó, I., & Gianotti, M. (2012) · Biochemistry and Cell Biology · doi:10.1139/o11-069 · Cited by 32
The cardiovascular effects of the thiazolidinediones: a review of the clinical data
Kelly, A. S., & Bank, A. J. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.03.006 · Cited by 32
Decreased gene expression of insulin signaling genes in insulin sensitive tissues of obese cats
Mori, A., Lee, P., Takemitsu, H., Iwasaki, E., Kimura, N., Yagishita, M., Hayasaka, M., & Arai, T. (2008) · Veterinary Research Communications · doi:10.1007/s11259-008-9179-y · Cited by 32
Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
Ratziu, V., & Zelber‐Sagi, S. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.001 · Cited by 30
Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3′-kinase
Pereira, R. I., Leitner, J. W., Erickson, C. B., & Draznin, B. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.09.002 · Cited by 31
Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin
Viljanen, A. P. M., Virtanen, K. A., Järvisalo, M. J., Hällsten, K., Parkkola, R. K., Rönnemaa, T., Lönnqvist, F., Iozzo, P., Ferrannini, E., & Nuutila, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1073 · Cited by 32
Congenital Lipodystrophies and Dyslipidemias
Prieur, X., May, C. L., Magré, J., & Cariou, B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0437-x · Cited by 33
Nonalcoholic Hepatic Steatosis in Zucker Diabetic Rats: Spontaneous Evolution and Effects of Metformin and Fenofibrate
Forcheron, F., Abdallah, P., Basset, A., del Carmine, P., Haffar, G., & Beylot, M. (2009) · Obesity · doi:10.1038/oby.2008.661 · Cited by 30
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
Schernthaner, G.-H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02025.x · Cited by 30
Rosiglitazone Inhibits Hepatic Insulin Resistance Induced by Chronic Pancreatitis and IKK-β/NF-κB Expression in Liver
Zhou, X., & You, S. (2014) · Pancreas · doi:10.1097/mpa.0000000000000173 · Cited by 30
In Vivo Metabolic Phenotyping of Myocardial Substrate Metabolism in Rodents
Shoghi, K. I., Finck, B. N., Schechtman, K. B., Sharp, T. L., Herrero, P., Gropler, R. J., & Welch, M. J. (2009) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.108.843227 · Cited by 30
Involvement of adipose tissues in the early hypolipidemic action of PPARγ agonism in the rat
Laplante, M., Festuccia, W. T., Soucy, G., Gélinas, Y., Lalonde, J., & Deshaies, Y. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00761.2006 · Cited by 32
The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial
Stone, M., Walker, J. L., Chisholm, D. J., Craig, M. E., Donaghue, K. C., Crock, P., Anderson, D., & Verge, C. F. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00383.x · Cited by 29
Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice
Du, T., Yang, L., Xu, X., Shi, X., Xu, X., Lu, J., Lv, J., Huang, X., Chen, J., Wang, H., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0432 · Cited by 31
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
Green, C., Marjot, T., Tomlinson, J., & Hodson, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13592 · Cited by 29
Downregulation of ADIPOQ and PPARγ2 Gene Expression in Subcutaneous Adipose Tissue of Obese Adolescents With Hepatic Steatosis
Kursawe, R., Narayan, D., Cali, A. M. G., Shaw, M. M., Pierpont, B. M., Shulman, G. I., & Caprio, S. (2010) · Obesity · doi:10.1038/oby.2010.23 · Cited by 29
Hypoglycemic Properties of the Aqueous Extract from the Stem Bark of Ceiba pentandra in Dexamethasone‐Induced Insulin Resistant Rats
Fofié, C. K., Nguelefack‐Mbuyo, E. P., Tsabang, N., Kamanyi, A., & Nguelefack, T. B. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/4234981 · Cited by 30
Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome
Jahn, L. A., Hartline, L. M., Liu, Z., & Barrett, E. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00287.2021 · Cited by 28
Is liver disease a threat to patients with metabolic disorders?
Marchesini, G., Forlani, G., & Bugianesi, E. (2005) · Annals of Medicine · doi:10.1080/07853890510011445 · Cited by 28
Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb06 · Cited by 28
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION
Ekholm, E., Hansen, L., JOHNSSON, E. K., Iqbal, N., Carlsson, B., Chen, H., & Hirshberg, B. (2016) · Endocrine Practice · doi:10.4158/ep161323.or · Cited by 27
Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes
Liu, Z., Xu, L., Xing, M., Xu, X., Wei, J., Wang, J., & Kang, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109952 · Cited by 27
The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV‐Infected Patients
Sutinen, J. (2008) · PPAR Research · doi:10.1155/2009/373524 · Cited by 26
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 26
PPAR-γ Agonist Pioglitazone Restored Mouse Liver mRNA Expression of Clock Genes and Inflammation-Related Genes Disrupted by Reversed Feeding
Fedchenko, T., Izmailova, O. V., Shynkevych, V. І., Shlykova, O. A., & Кайдашев, І. П. (2022) · PPAR Research · doi:10.1155/2022/7537210 · Cited by 26
The double trouble of metabolic diseases: the diabetes–cancer link
Tudzarova, S., & Osman, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-11-1550 · Cited by 26
Effect of dabai (Canarium odontophyllum) fruit extract on biochemical parameters of induced obese–diabetic rats
Mokiran, N. N., Ismail, A., Azlan, A., Hamid, M., & Hassan, F. A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.03.007 · Cited by 26
Distinct metabolic effects following short-term exposure of different high-fat diets in male and female mice
Kumar, S. P. S., Shen, M., Spicer, E. G., Goudjo-Ako, A. J., Stumph, J. D., Zhang, J., & Shi, H. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0455 · Cited by 26
Thiazolidinediones for the Treatment in NASH
Argo, C. K., Iezzoni, J. C., Al‐Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31818f4fc2 · Cited by 26
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects
Tamura, Y., Watada, H., Sato, F., Kumashiro, N., Sakurai, Y., Hirose, T., Tanaka, Y., & Kawamori, R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00801.x · Cited by 26
The Effects of Macronutrient Intake on Total and High‐molecular Weight Adiponectin: Results From the OMNI‐Heart Trial
Yeung, E. H., Appel, L. J., Miller, E. R., & Kao, W. H. L. (2009) · Obesity · doi:10.1038/oby.2009.402 · Cited by 30
Dai-Zong-Fang, A Traditional Chinese Herbal Formula, Ameliorates Insulin Resistance in db/db Mice
Zhu, L., Zhu, X., Sun, G., Meng, X., Wang, M., Cui, H., Wang, J., Zhai, Y., Yang, K., Tang, Y., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00224 · Cited by 25
Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients
Bouras, H., Roig, S. R., Kurstjens, S., Tack, C. J., Kebieche, M., de Baaij, J. H. F., & Hoenderop, J. G. J. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0570 · Cited by 24
Long‐term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes
Bell, D. S. H., & Ovalle, F. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00560.x · Cited by 24
The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes
Göke, B., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.041 · Cited by 24
Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies
Goto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 28
Clinical association between serum γ‐glutamyltransferase levels and the development of insulin resistance in Korean men: a 5‐year follow‐up study
Ryoo, J., Oh, C., Kim, H. S., Park, S. K., & Choi, J. (2013) · Diabetic Medicine · doi:10.1111/dme.12315 · Cited by 23

Authors: Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H.
Affiliations: University of Helsinki (FI)
Department of Medicine, Division of Oncology, University of Helsinki, Helsinki, Finland
Minerva Foundation (FI)
Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
Venue: Diabetes
Publisher: American Diabetes Association
Published: 2004-08-01
Volume: 53
Issue: 8
Pages: 2169-2176
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.53.8.2169
OpenAlex: W2107068945
Cited by: 524
References: 48
Citations by year: 2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 15 · 2017: 12 · 2016: 18 · 2015: 19 · 2014: 24 · 2013: 26 · 2012: 15
FWCI: 34.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
Funders: Suomen Lääketieteen Säätiö
Biomedicum Helsinki-säätiö
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords: rosiglitazone, metformin, type 2 diabetes, hepatic insulin resistance, hepatic insulin sensitivity, liver fat, insulin clearance, adiponectin, adipose tissue gene expression, PPARγ, lipoprotein lipase, insulin-stimulated glucose uptake, 1H NMR, drug comparison, weight loss, HbA1c
MeSH terms: Rosiglitazone, Adipose Tissue, Cholesterol, Diabetes Mellitus, Type 2, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Male, Metformin, Middle Aged, Triglycerides, Thiazolidinediones, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks